GCM
AXSM icon

Gunpowder Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Gunpowder Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.22K Hold
5
– – ﹤0.01% 364
2026
Q1 		$845 Hold
5
– – ﹤0.01% 372
2025
Q4 		$913 Buy
+5
New +$698 ﹤0.01% 394

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Gunpowder Capital Management's AXSM Position: Q2 2026 in Review

Gunpowder Capital Management held its Axsome Therapeutics (AXSM) position steady in Q2 2026 at 5 shares worth $1.22K. The position accounts for ﹤0.01% of the portfolio, ranked #364.

Gunpowder Capital Management first reported a position in AXSM in Q4 2025 and has held it in 3 quarters since. 502 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Gunpowder Capital Management held 5 shares of Axsome Therapeutics worth $1.22K as of Q2 2026.
  • Gunpowder Capital Management left its Axsome Therapeutics share count unchanged in Q2 2026.
  • Axsome Therapeutics made up ﹤0.01% of Gunpowder Capital Management's portfolio in Q2 2026, its #364 holding.
  • Gunpowder Capital Management first reported a position in Axsome Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 502 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Gunpowder Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.